D9Z Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryMulti-year organic revenue growth with a marked TTM acceleration indicates expanding patient volumes and stronger clinic utilization. Durable top-line momentum supports scale advantages in purchasing, fixed-cost absorption and continued investment in clinical capacity over the next 2–6 months.
Sustained ProfitabilityConsistently high operating and EBITDA margins reflect efficient clinic operations and favorable procedure mix. Durable margins support cash flow generation, enable reinvestment in technology and staffing, and provide resilience to moderate volume swings across the network over the medium term.
Strong Cash GenerationOCF reliably above net income signals high earnings quality and real cash conversion from clinic services. Positive free cash flow, despite volatility, funds capex, clinic upgrades and shareholder returns while preserving financial flexibility for measured expansion or debt paydown.
Bears Say
Leverage Remains MeaningfulAlthough leverage has improved, absolute debt levels have not declined materially, leaving balance sheet sensitivity to slower cash flow or cyclical dips. Meaningful leverage can restrict strategic flexibility for M&A, larger capital projects or rapid share buybacks if earnings soften.
Free Cash Flow VolatilityVariability in FCF reflects capex timing and reinvestment in clinics; this unpredictability complicates planning for dividends, debt reduction or expansion. Persistent FCF volatility could constrain consistent return of capital or slow opportunistic investments during downturns.
Exposure To Elective ProceduresConcentration in elective ophthalmic procedures makes revenue sensitive to consumer demand, macro conditions and competitive pricing. Structural reliance on out-of-pocket or partially reimbursed services increases cyclicality and geographic reimbursement risk over the medium term.
Clinica Baviera News
D9Z FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Currently, no data Available
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is CHF891.93M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Jul 27, 2027 which is in 361 days.
How were Clinica Baviera, SA’s earnings last quarter?
Currently, no data Available
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Undervalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA does not currently pay dividends.
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in CH:D9Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.